Public data, as of November 2026
The Data Hub has no reported emissions for this company yet, so there is no footprint to summarize.
Near-term status: Commitment to Set Targets. Net-zero status: no net-zero target on record.
Scope 3 appears once a full disclosure is matched.
A peer comparison appears once sector peers report their emissions.
No voluntary retirement names this company as beneficiary yet.
tCO₂e, GHG Protocol scopes
Peers: companies in the SBTi industry "Pharmaceuticals, Biotechnology and Life Sciences", by Scope 3 share of the latest reported footprint.
Tell us what you would like to know about these emissions, targets or suppliers. A person on the Carbon3 team reads every message and replies by email.
No reported emissions for this company yet
Carbon3 compiles emissions from published sustainability reports and normalizes them to the GHG Protocol scopes. This company has not been covered yet, or has not published figures that could be read reliably.
Scope 3 categories are not itemized yet
Categories appear once a published disclosure splits Scope 3 into the GHG Protocol categories.
Status as published by the SBTi
Primary SBTi record: 10x Genomics
Carbon3 shows each record exactly as the SBTi publishes it, and does not assess, rate or endorse targets. A validated target says nothing about any market instrument.
Registry records naming the company as beneficiary
No voluntary credit retirements linked to this company
Carbon3 has not found a retirement in the public voluntary carbon market registry data it tracks that names this company as the beneficiary.
The median appears when at least one peer reports all three scopes.
6 of 6 named peers report all three scopes, so their Scope 3 share can be compared.
Cached 18 Aug 2026
10x Genomics has committed to near-term science-based emissions reduction targets through the Science Based Targets initiative, with validated goals covering full supply chain in the biotech sector. The company targets a 62% reduction in total GHG emissions by 2030 from a 2019 baseline across Scope 1, 2, and 3, near-zero emissions in direct operations and purchased energy by 2025, and a 50% reduction in Scope 3 emissions intensity by 2040. To support these targets, 10x Genomics has entered power purchase agreements for renewable electricity, partnered on regenerative agriculture for reagents, launched a recycling program for plastic consumables, engaged suppliers on decarbonization, and optimized logistics with partners including NextEra Energy, First Climate, TerraCycle, Thermo Fisher Scientific, and DHL. These actions and partnerships with organizations such as the Pharmaceutical Supply Chain Initiative and Oracle Corporation allow the company to implement emissions reductions across operations and the value chain while improving supply chain transparency.
This report is generated by AI from public sources and may contain errors, so readers should check the linked sources before relying on it.
10x Genomics has committed to near-term science-based emissions reduction targets through the Science Based Targets initiative (SBTi), with validated goals covering full supply chain.
Validated SBTi target to reduce total GHG emissions by 62% by 2030 versus 2019 baseline, including Scope 1, 2, and 3.
Aims for near-zero emissions in direct operations and purchased energy by 2025.
Target of 50% reduction in Scope 3 emissions intensity across purchased goods, services, and logistics by 2040.
Achieved UN SDG ESG Transparency Score of 4.0 overall, with environmental score of 3.4 and social score of 4.0.
Emerging projects catalog, status as reported by each project
No projects linked to this company yet
Carbon3 has not yet found a public decarbonization project that names this company.
No inset projects are listed for this company yet.
Suppliers to 10x Genomics, Inc. can list a reduction project on Carbon3 at no cost, so that the company could co-fund it.